bi 425809

Small moleculeexperimental

Clinical trial activity

28 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
21
Phase 2
7
Phase 3
4
Phase 4
0

Earliest trial started Mar 1, 2014 (NCT02068690)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1C[C@@H]2C[C@]2(c2cc(C(F)(F)F)on2)C1)C(F)(F)F
Mol. weight
512.43 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bi 425809

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06070597Phase 1Jan 25, 2024Boehringer Ingelheim
NCT05731895Phase 1Mar 8, 2023Boehringer Ingelheim
NCT05723874Phase 1Mar 6, 2023Boehringer Ingelheim
NCT05718843Phase 1Feb 1, 2023Boehringer Ingelheim
NCT05613777Phase 1Nov 24, 2022Boehringer Ingelheim
NCT05347004Phase 1Oct 25, 2022Boehringer Ingelheim
NCT05258110Phase 1Mar 18, 2022Boehringer Ingelheim
NCT05211947Phase 3Mar 3, 2022Boehringer Ingelheim
NCT05076409Phase 1Oct 19, 2021Boehringer Ingelheim
NCT04860830Phase 3Jun 18, 2021Boehringer Ingelheim
NCT04846868Phase 3Jun 16, 2021Boehringer Ingelheim
NCT04846881Phase 3Jun 7, 2021Boehringer Ingelheim
NCT04602221Phase 1Dec 1, 2020Boehringer Ingelheim
NCT03988803Phase 1Jul 5, 2019Boehringer Ingelheim
NCT03859973Phase 2Apr 15, 2019Boehringer Ingelheim
NCT03905096Phase 1Apr 12, 2019Boehringer Ingelheim
NCT03817476Phase 1Feb 11, 2019Boehringer Ingelheim
NCT03783000Phase 1Jan 15, 2019Boehringer Ingelheim
NCT03654170Phase 1Sep 11, 2018Boehringer Ingelheim
NCT03082183Phase 1Mar 28, 2017Boehringer Ingelheim
Showing 20 of 28 trials
Page 1 / 2

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit282832014
1 organizations
Page 1 / 1